SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced finan…
Category: Business
Glaukos and Avedro Announce Definitive Acquisition Agreement
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, and Avedro, Inc. (Nas…
Glaukos and Avedro Announce Definitive Acquisition Agreement
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, and Avedro, Inc. (Nas…
Aerie Pharmaceuticals Reports Second Quarter 2019 Financial Results, Updates Full-Year 2019 Guidance and Provides Business Update
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucom…
Aerie Pharmaceuticals Reports Second Quarter 2019 Financial Results, Updates Full-Year 2019 Guidance and Provides Business Update
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucom…
Ocular Therapeutix™ Reports Second Quarter 2019 Financial Results and Business Update
BEDFORD, Mass.–(BUSINESS WIRE)–<a href="https://twitter.com/search?q=%24OCUL&src=ctag" target="_blank">$OCUL</a> <a href="https://twitter.com/hashtag/OCUTX?src=hash" target="_blank">#OCUTX…
Ocular Therapeutix™ Reports Second Quarter 2019 Financial Results and Business Update
BEDFORD, Mass.–(BUSINESS WIRE)–<a href="https://twitter.com/search?q=%24OCUL&src=ctag" target="_blank">$OCUL</a> <a href="https://twitter.com/hashtag/OCUTX?src=hash" target="_blank">#OCUTX…
NuSight Medical Sells 5,000 NuLids Systems
RANCHO SANTA FE, Calif.–(BUSINESS WIRE)–Sale of 5,000 NuLids supports doctors and patients belief and value in NuLids
IVERIC bio to Present at the Wedbush PacGrow Healthcare Conference
NEW YORK–(BUSINESS WIRE)–IVERIC bio announced that Glenn P. Sblendorio, CEO & President, will present an overview of the Company at the Wedbush PacGrow Healthcare Conference.
Second Sight Reports Second Quarter 2019 Financial Results
LOS ANGELES–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision…
Stephen Woods, CFA, CPA, Joins Eyecare Services Partners as Vice President of Finance
DALLAS–(BUSINESS WIRE)–Eyecare Services Partners (ESP), the national leader in integrated eye care services, announced that Stephen Woods, CFA, CPA, has joined the Company as Vice President of Finance effective July 29. Mr. Woods reports to Chief Fin…
Zenni Brings Iconic Character Looks to Life from Smash Broadway Musical Tootsie as Official Eyewear Partner
NOVATO, Calif. & NEW YORK–(BUSINESS WIRE)–<a href="https://twitter.com/hashtag/Collection?src=hash" target="_blank">#Collection</a>–Zenni, the online optical industry leader, and Tootsie the Musical are proud to i…
Omeros and Lonza Enter Long-Term Manufacturing Agreement for Commercial Supply of Narsoplimab
SEATTLE & BASEL, Switzerland–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER) and Lonza (SWX: LONN) today announced a long-term manufacturing agreement for commercial production of narsoplimab, Omeros’ lead human monoclonal antibody targeting ma…
Second Sight to Discuss Second Quarter 2019 Financial Results on August 6, 2019 Conference Call
LOS ANGELES–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics intended to create an artificial form of useful vision for blind individuals, will release its fi…
Second Sight to Discuss Second Quarter 2019 Financial Results on August 6, 2019 Conference Call
LOS ANGELES–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics intended to create an artificial form of useful vision for blind individuals, will release its fi…
Second Sight to Discuss Second Quarter 2019 Financial Results on August 6, 2019 Conference Call
LOS ANGELES–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics intended to create an artificial form of useful vision for blind individuals, will release its fi…
My Eyelab, un proveedor líder de salud oftalmológica, se expande en el área de Dallas/Ft. Worth con ocho nuevas tiendas, un crecimiento que creará aproximadamente 50 puestos de trabajo en el área
DALLAS–(BUSINESS WIRE)–My Eyelab, una marca minorista de Now Optics, un proveedor líder de salud oftalmológica que ofrece servicios para el cuidado de la vista y lentes accesibles y económicos, anunció hoy una mayor presencia minorista en ocho locali…
My Eyelab, a Leading Eye Health Provider, Expands in Dallas/Ft. Worth with Eight New Stores, Growth Brings Approximately 50 Jobs to Area
DALLAS–(BUSINESS WIRE)–<a href="https://twitter.com/hashtag/EyeExam?src=hash" target="_blank">#EyeExam</a>–My Eyelab, a retail brand of Now Optics, which is a leading eye health provider offering accessible and afford…
Ocular Therapeutix™ Announces Early Assignment of Permanent and Specific J-Code (J1096) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4mg by the Centers for Medicare and Medicaid Services
BEDFORD, Mass.–(BUSINESS WIRE)–<a href="https://twitter.com/search?q=%24OCUL&src=ctag" target="_blank">$OCUL</a> <a href="https://twitter.com/hashtag/OCUTX?src=hash" target="_blank">#OCUTX…
Aerie Pharmaceuticals to Announce Second Quarter 2019 Financial Results and Host Conference Call on Wednesday, August 7, 2019
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucom…